Galecto Inc.
Galecto Inc. is listed today as Damora Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2025 | $285 M | Private placement after listing | $250 million to $1 billion | equity | SEC | |
| Sep 2020 | $64 M | No. 1 | $50 to $250 million | equity | SEC | |
| Dec 2019 | $79 M | Issued in a merger or acquisition | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Galecto Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2025).
SEC Form D · Nov 2025
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Nov 2025
That is all the official record says: Galecto Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Galecto Inc. are on record.
Investors#
14 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Amit Munshi | Person | not stated | not stated | Held Series D preferred stock, director (Form 3, 2020) | SEC Form 3 |
| Anders Pedersen | Person | not stated | not stated | Held Series C-1 preferred stock (Form 3, 2020) | SEC Form 3 |
| Carl Goldfischer | Person | not stated | not stated | Held Series D preferred stock, director (Form 3, 2020) | SEC Form 3 |
| Fairmount Funds Management LLC | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner, director (Form 3, 2025) | SEC Form 3 |
| Fairmount Healthcare Co-Invest V L.P. | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2025) | SEC Form 3 |
| Fairmount Healthcare Fund II L.P. | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2025) | SEC Form 3 |
| Hans T. Schambye | Person | not stated | not stated | Held Series C-1 preferred stock, director (Form 3, 2020) | SEC Form 3 |
| Julianne Bruno | Person | not stated | not stated | Held Series C preferred stock, director (Form 3, 2025) | SEC Form 3 |
| Novo Holdings A/s | Fund or asset manager | not stated | not stated | Held Series B-1, B-2, B-3, B-4, C-1, C-2, C-4, C-5 and D preferred (Form 3, 2020 | SEC Form 3 |
| OrbiMed Advisors Israel II Ltd | Fund or asset manager | not stated | not stated | Held Series C-2, C-4, C-5 and D preferred (Form 3, 2020) | SEC Form 3 |
| Orbimed Advisors LLC | Fund or asset manager | not stated | not stated | Held Series C-2, C-4, C-5 and D preferred (Form 3, 2020) | SEC Form 3 |
| OrbiMed Capital GP VII LLC | Fund or asset manager | not stated | not stated | Held Series C-2, C-4, C-5 and D preferred (Form 3, 2020) | SEC Form 3 |
| OrbiMed Genesis GP LLC | Other | not stated | not stated | Held Series C-2, C-4, C-5 and D preferred (Form 3, 2020) | SEC Form 3 |
| OrbiMed Israel GP II, L.P. | Fund or asset manager | not stated | not stated | Held Series C-2, C-4, C-5 and D preferred (Form 3, 2020) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 42 investors.
Largest shareholders today
Institutions holding Damora Therapeutics, Inc. shares, as of Sep 30, 2026.
- FMR LLC$203 M15.43%
- Fairmount Funds Management LLC$185 M14.07%
- Avoro Capital Advisors LLC$81 M6.11%
- Venrock Adviser, LLC$77 M5.82%
- BlackRock, Inc.$75 M5.68%
- Ra Capital Management, L.P.$51 M3.88%
- Remedium Capital Partners, LLC$44 M3.30%
- Commodore Capital LP$41 M3.13%
- Bellevue Group AG$41 M3.10%
- Jpmorgan Chase & Co$40 M3.02%
- State Street Corp$38 M2.88%
- Braidwell LP$37 M2.82%
- Viking Global Investors LP$26 M1.95%
- Geode Capital Management, LLC$26 M1.94%
- UBS Group AG$23 M1.75%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Garrett T. Winslow | Executive officer | Nov 2025 |
| Hans T. Schambye | Executive officer | Nov 2025 |
| Lori T. Firmani | Executive officer | Nov 2025 |
| Hans Schambye | Executive officer | Nov 2020 |
| Jon Freve | Executive officer | Nov 2020 |
| Jakob Dynnes Hansen | Executive officer | Jan 2020 |
| Amit T. Munshi | Director | Nov 2025 |
| Carl T. Goldfischer | Director | Nov 2025 |
| Christopher T. Cain | Director | Nov 2025 |
| Hans T. Schambye | Director | Nov 2025 |
| Jayson T. Dallas | Director | Nov 2025 |
| Julianne T. Bruno | Director | Nov 2025 |
| Peter T. Harwin | Director | Nov 2025 |
| Amit Q. Munshi | Director | Nov 2020 |
| Carl Q. Goldfischer | Director | Nov 2020 |
| Chandra Q. Leo | Director | Nov 2020 |
| Chao Q. Khuong | Director | Nov 2020 |
| David Q. Shapiro | Director | Nov 2020 |
| Erez Q. Chimovits | Director | Nov 2020 |
| Hans Schambye | Director | Nov 2020 |
| Karen Wagner | Director | Nov 2020 |
| Soren Q. Lemonius | Director | Nov 2020 |
| Soren Q. Moller | Director | Nov 2020 |
| Stephan Q. Christgau | Director | Nov 2020 |
Went public since 2020. Its SEC number is that of a company listed on a stock exchange.